CFTR activity is enhanced by the novel corrector GLPG2222, given with and without ivacaftor in two randomized trials

Author:

Bell Scott C.,Barry Peter J.,De Boeck Kris,Drevinek PavelORCID,Elborn J. Stuart,Plant Barry J.,Minić Predag,Van Braeckel Eva,Verhulst Stijn,Muller Karine,Kanters Desirée,Bellaire Susan,de Kock Herman,Geller David E.,Conrath Katja,Van de Steen Olivier,van der Ent Kors

Funder

Galapagos NV

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Pediatrics, Perinatology, and Child Health

Reference28 articles.

1. EPS3.05 GLPG2222 in subjects with cystic fibrosis homozygous for F508del: results from a phase II study (FLAMINGO);van der Ent;J Cyst Fibros,2018

2. WS01.4 GLPG2222 in subjects with cystic fibrosis and the F508del/class III mutation on stable treatment with ivacaftor: results from a phase II study (ALBATROSS);Bell;J Cyst Fibros,2018

3. Results from a phase II study - ALBATROSS - evaluation of GLPG2222 in subjects with CF and the F508del/classIII mutation on stable treatment with ivacaftor. Abstract 269;Bell;Pediatr Pulmonol,2018

4. GLPG2222 in CF subjects homozygous for F508del: results from a phase II study (FLAMINGO). Abstract 271;van der Ent;Pediatr Pulmonol,2018

5. Cystic fibrosis: current therapeutic targets and future approaches;Rafeeq;J Transl Med,2017

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3